Stock Evaluator: Aspen Pharmacare Holdings Limited (APNHY)

Aspen Pharmacare Holdings Limited APNHY

$8.89 -0.10 -1.06%
July 31, 2026 2:39:58 PM EST November 10, 2021 Volume: 101
After Hours: $120.37   0.15  |  0.12% November 10, 2021 7:59 PM EST Volume: 72,713
USD | DELAYED PRICE
SECTOR INDUSTRY
Health Care Pharmaceuticals

A+ Stock Grade Summary:

VALUE:
GROWTH:
MOMENTUM:
EPS REVISIONS:
QUALITY:
COMPANY SUMMARY
Aspen Pharmacare Holdings Limited, together with its subsidiaries, manufactures and markets specialty and branded pharmaceutical products in Africa, the Middle East, the Americas, Europe CIS, Australasia, and Asia. It operates through Commercial Pharmaceuticals and Manufacturing segments. The company offers injectables for therapeutic areas, such as anaesthetics, anticoagulants, antithrombotic agents, analgesics, and hormone replacement medicines under the Arixtra, Diprivan, Fraxiparine, Marcaine, Sustanon, and Xylocaine brands; over-the-counter medicines under the Emla, Maltofer, Ovestin, Solpadeine, and Xylocaine brands; and prescription products for anti-inflammatories, immunosuppressants, hypothyroidism, anti-gout, analgesics, and corticosteroids under the Eltroxin, Imuran, Lipitor, Lyrica, and Zyloric brands. It also manufactures active pharmaceutical ingredients, finished dose forms, and heparins, as well as steriles, oral solid doses, liquids, semi-solids, and biologicals. The company exports its products. Aspen Pharmacare Holdings Limited was founded in 1850 and is headquartered in Durban, South Africa.

Financial Summary

Share Statistics APNHY Industry
Median
Percentile
(All Stocks)
Market Cap (Mil) $4,001.2 $579.1 64%
Shares Out (Mil) 26.9 43.0 35%
Institutional Ownership 38.4% 84.3% 16%
Float (Mil) 366.1 46.8 82%
Beta 0.34 0.62 19%
Avg Daily Volume (000s) 1 285 4%
Price Change
(52-week)
(29.2%) 63.8% 25%
Growth APNHY Industry
Median
Percentile
(All Stocks)
Sales (5yr) 4.7% 6.7% 35%
Net Income (5yr) (17.4%) (1.4%) 23%
EPS (5yr) (17.4%) 14.9% 16
Dividends (5yr) 0.0% 0.0% 58%
Cash Flow (5yr) (9.5%) (14.9%) 59%
Estimates Qtrly Current
Fiscal
Year
Next
Fiscal
Year
# of Estimates na na na
Current EPS na na na
Month Ago EPS na na na
# Rev Up na na na
# Rev Down na na na
Three Months Ago EPS na na na
Year/Year Chg na na na
Financials APNHY Industry
Median
Percentile
(All Stocks)
Sales (TTM) (Mil) $2,572 $272 64%
Net Income (TTM) (Mil) ($121) ($11) 9%
EPS (TTM) ($0.272) ($0.500) 32%
Operating Cash Flow (TTM) (Mil) $419 ($6) 69%
Net Cash Flow (TTM) (Mil) ($8) $4 32%
Long-Term Debt (Q1) (Mil) $1,772 $7 73%
Enterprise Value (Q1) (Mil) $5,430 $522 64%
Valuation APNHY Industry
Median
Percentile
(All Stocks)
P/B na 2.73 na
P/E na 20.5 na
Dividend Yield na 0.0% na
PEG (5yr hist) na 1.2 na
Ratios APNHY Industry
Median
Percentile
(All Stocks)
Gross Margin 43.0% 65.9% 53%
Net Margin (4.7%) 0.7% 25%
ROA (1.6%) (24.6%) 35%
ROE (2.6%) (19.7%) 33%
Liabilities to Assets 36.7% 35.5% 27%
F-Score na 3 na

Aspen Pharmacare Holdings Limited did not pass any screens on 7/31/2026.

Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.

Ⓒ 2026 American Association of Individual Investors